AstraZeneca has announced a $1.28B plan to purchase TeneoTwo, a U.S. oncology firm. AstraZeneca said the purchase will be focused on a molecule made by the company that is designed to encourage the body's immune system to target and kill cancer cells.
Click here to read the entire article.